Deaths and disability from natalizumab are no longer tolerable: Commentary

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1073-

  Hutchinson, Michael ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; NATALIZUMAB;

CLINICAL PRACTICE; DENMARK; DISEASE CONTROL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIFE EXPECTANCY; MULTIPLE SCLEROSIS; NOTE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 84864136597     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512451947     Document Type: Note

References (4)

1. Polman CH, O'Connor PW, Havrdova E, et al. for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med. 2006 ; 354: 899-910
2. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. 2004 ; 127: 844-850
3. Koch-Henriksen N, Brønnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998 ; 65: 56-59
4. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler J. 2010 ; 16: 1507-1512